Advances in Planar Lipid Bilayers and Liposomes Editorial Board

Total Page:16

File Type:pdf, Size:1020Kb

Advances in Planar Lipid Bilayers and Liposomes Editorial Board VOLUME NINE ADVANCES IN PLANAR LIPID BILAYERS AND LIPOSOMES EDITORIAL BOARD Professor Dr. Roland Benz (Wuerzburg, Germany) Professor Dr. Hans G.L. Coster (Sydney, Australia) Professor Dr. Herve Duclohier (Rennes, France) Professor Dr. Yury A. Ermakov (Moscow, Russia) Professor Dr. Alessandra Gliozzi (Genova, Italy) Professor Dr. Alesˇ Iglicˇ (Ljubljana, Slovenia) Professor Dr. Bruce L. Kagan (Los Angeles, USA) Professor Dr. Wolfgang Knoll (Mainz, Germany) Professor Dr. Reinhard Lipowsky (Potsdam, Germany) Professor Dr. Yoshinori Muto (Gifu, Japan) Professor Dr. Ian R. Peterson (Coventry, UK) Professor Dr. Alexander G. Petrov (Sofia, Bulgaria) Professor Dr. Jean-Marie Ruysschaert (Bruxelles, Belgium) Professor Dr. Bernhard Schuster (Vienna, Austria) Professor Dr. Masao Sugawara (Tokyo, Japan) Professor Dr. Yoshio Umezawa (Tokyo, Japan) Professor Dr. Erkang Wang (Changchun, China) Professor Dr. Philip J. White (Wellesbourne, UK) Professor Dr. Mathias Winterhalter (Bremen, Germany) Professor Dr. Dixon J. Woodbury (Provo, USA) VOLUME NINE ADVANCES IN PLANAR LIPID BILAYERS AND LIPOSOMES Editor PROFESSOR DR. A. LEITMANNOVA LIU Department of Physiology, Michigan State University, East Lansing, Michigan, USA and Centre for Interface Sciences, Microelectronics Department, Faculty of Electrical Engineering & Information Technology, Slovak Technical University, Bratislava, Slovak Republic Founding Editor PROFESSOR DR. H.T. TIEN Department of Physiology, Michigan State University, East Lansing, Michigan, USA Amsterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore Sydney Tokyo Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier Linacre House, Jordan Hill, Oxford OX2 8DP, UK 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, California 92101-4495, USA First edition 2009 Copyright # 2009 Elsevier Inc. All rights reserved No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) 1865 843830, fax: (+44) 1865 853333; E-mail: [email protected]. You may also complete your request online via the Elsevier homepage (http://elsevier.com), by selecting ‘‘Support & Contact’’then ‘‘Copyright and Permission’’ and then ‘‘Obtaining Permissions’’ Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library ISBN: 978-0-12-374822-5 ISSN: 1554-4516 For information on all Academic Press publications visit our website at www.elsevierdirect.com Printed and bound in USA 08 09 10 11 12 10 9 8 7 6 5 4 3 2 1 CONTENTS Preface xi Contributors xiii 1. Current Perspectives in Liposome-Encapsulated Hemoglobin as Oxygen Carrier 1 Hrushikesh Agashe and Vibhudutta Awasthi 1. Introduction 2 2. Lipid Composition of LEH 4 3. PEG Modification of LEH Surface 6 4. Hemoglobin Source 7 5. Particle Size 8 6. Hemoglobin and Oxygen Affinity 9 7. Viscosity of LEH Preparation 11 8. Oncotic Pressure and Isotonocity 12 9. Hemoglobin Auto-oxidation and Methemoglobin Formation 13 10. Current Manufacturing Technology 15 11. Toxicological Issues 16 12. In Vivo Biodisposition 18 13. Physiological and Survival Studies in Animal Models of Hemorrhagic Shock 20 14. Summary 20 Acknowledgments 21 References 21 2. Electric Conductance of Planar Lipid Bilayer as a Tool for the Study of Membrane Pore Selectivity and Blockade 29 Valery F. Antonov, Vladimir P. Norik, and Elena Yu. Smirnova 1. Introduction 30 1.1. Theoretical Background 32 1.2. Formulation of the Experimental Problem 39 2. Experimental 39 2.1. Lipids 39 2.2. Poly(ethylene)glycols 39 2.3. Differential Scanning Calorimetry 40 v vi Contents 2.4. Planar BLMs 40 2.5. Electrical Measurements 40 2.6. Lipid Pore Size Evaluation 40 2.7. Poly(ethylene)glycol Method 40 2.8. Estimation of Membrane Surface Tension s 41 2.9. Estimation of Single Lipid Pore Edge Tension g 42 3. Results 43 3.1. Registration of Lipid Pore Population Appeared in pBLM from DPPC at the Lipid Phase Transition Temperature 43 3.2. Lipid Phase Transition in pBLM and Electric Current Fluctuations 45 3.3. The Appearance of Single Lipid Pores in the pBLM from Natural Phospholipids 48 3.4. Line Edge Tension of Lipid Pore 48 3.5. Evaluation of Lipid Bilayer Stability 50 3.6. Blocking Effect of PEGs on Single Lipid Pore Conductance 52 4. Discussion 59 5. Conclusion 61 Acknowledgments 62 References 62 3. Physicochemical and Pharmacokinetic Characterization of Ultradeformable Vesicles using Calcein as Hydrophilic Fluorescent Marker 65 Ana Paula Correˆa Oliveira Bahia, Larissa Barbosa Rabelo, Warley Cristiano Souza, Lucas Antonio Miranda Ferreira, and Fre´de´ric Fre´zard 1. Introduction 66 2. Physicochemical Characterization of Ultradeformable Vesicles 68 2.1. Composition and Process of Preparation 68 2.2. Mean Hydrodynamic Diameter and Deformability 69 2.3. Encapsulation Efficiency of Calcein: Influence of the Formulation Final Concentration 69 2.4. Membrane Permeability to Calcein 71 3. Pharmacokinetics of Calcein from Ultradeformable Vesicles 73 3.1. In Vitro Skin Permeation of Calcein 73 3.2. In Vivo Studies of the Transdermal Absorption of Calcein to the Blood Circulation 76 4. Concluding Remarks: New Model for the Mode of Action of Ultradeformable Vesicles 81 Acknowledgments 84 References 84 Contents vii 4. Electrical Methods for Determining Surface Charge Density and Electrolyte Composition at the Lipid Bilayer-Solution Interface 87 Derek Laver 1. Introduction 88 2. Bilayer Capacitance as a Probe for Bilayer Surface Potential 91 3. Apparatus for Measuring Perfusion Induced Current Transients in Lipid Bilayers 92 4. Exchange of Solutions Induced Bilayer Current Transient 94 5. Deriving Surface Potential and Surface Charge Density from Capacitive Current 96 6. Bilayer Capacitive Currents can be Used to Monitor Solution Exchange 100 7. Bilayer Capacitive Currents can be Used to Monitor Changes in Lipid Composition 101 8. Conclusions 103 Acknowledgments 103 References 103 5. Micropatterned Lipid Bilayer Membranes on Solid Substrates 107 Kenichi Morigaki 1. Introduction 108 1.1. Substrate-Supported Planar Lipid Bilayers 108 1.2. Micropatterning Substrate-Supported Planar Lipid Bilayers 108 1.3. Micropatterned Composite Membrane of Polymerized and Fluid Lipid Bilayers 109 2. Lithographic Polymerization of Lipid Bilayers 113 3. Incorporation of Fluid Lipid Bilayers 117 4. Controlling the Ratios of Polymerized and Fluid Lipid Bilayers 122 5. Incorporation of Biological Membranes into Micropatterned Bilayers 126 6. Conclusions and Outlook 128 Acknowledgments 129 References 130 6. Salt-Induced Morphological Transitions in Nonequimolar Catanionic Systems: Spontaneous Formation of Blastulae Aggregates 135 Nina Vlachy, Didier Touraud, and Werner Kunz 1. Introduction 136 1.1. Self-Assembly of Amphiphilic Molecules 136 1.2. Spontaneous Formation of Vesicles 137 1.3. Catanionic Surfactant Mixtures 139 viii Contents 1.4. Application of Catanionic Vesicles in Cosmetic and Drug Delivery 140 1.5. The Present Study 141 2. Experimental Procedures 142 2.1. Materials 142 2.2. Sample Preparation 142 2.3. Dynamic Light Scattering Measurements 142 2.4. Rheology 143 2.5. Cryo-Transmission Electron Microscopy (cryo-TEM) 143 2.6. Freeze-Fracture Electron Microscopy 143 3. Results 143 3.1. Characterization of SDS/DTAB Micellar Solution 143 3.2. Salt-Induced Micelle-to-Vesicle Transition 145 4. Discussion 149 4.1. Models of the Micelle-to-Vesicle Transition 149 4.2. Blastulae Vesicles 151 4.3. The Occurrence of Convex–Concave Patterns in Biological Systems 152 4.4. Raspberry Vesicles 153 4.5. Blastulae Vesicles: A General Trend in Catanionic Systems? 154 5. Conclusions 155 References 155 7. Transformation Between Liposomes and Cubic Phases of Biological Lipid Membranes Induced by Modulation of Electrostatic Interactions 163 Masahito Yamazaki 1. Introduction 164 2. Effects of Surface Charges due to Charged Lipids on the Stability of the Q Phases 171 3. Effects of Surface Charges due to Adsorbed Charged Peptides on the Stability of the Q Phases 176 4. Mechanism of the Electrostatic Interactions-Induced Phase Transition Between the Q Phase and the La Phase 181 2þ 5. Effects of Ca and pH on the Phase Transition Between the La Phase and the Q Phases 187 6. Effects of Charged Peptides and Osmotic Stress on the Stability of the Q Phases of the Charged Lipid Membranes 195 7. Conclusion 200 Appendix: Spontaneous Curvature of Monolayer Membranes 201 Acknowledgments 205 References 205 Contents ix 8. The Impact of Astrocytes in the Clearance of Neurotransmitters by Uptake and Inactivation 211 Katja Perdan, Metoda Lipnik-Sˇtangelj, and Mojca Krzˇan 1. Astrocytes 212 1.1. Structure 213
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0051633 A1 Harding Et Al
    US 20140051633A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0051633 A1 Harding et al. (43) Pub. Date: Feb. 20, 2014 (54) HEPATOCYTE GROWTH FACTOR MIMICS (60) Provisional application No. 61/706,567, filed on Sep. AS THERAPEUTICAGENTS 27, 2012, provisional application No. 61/706,437, filed on Sep. 27, 2012. (71) Applicant: Washington State University, Pullman, WA (US) Publication Classification (72) Inventors: Joseph W. Harding, Pullman, WA (US); John W. Wright, Pullman, WA (US); (51) Int. C. Caroline C. Benoist, Nashville, TN C07K5/065 (2006.01) (US); Leen H. Kawas, Pullman, WA (52) U.S. C. (US); Gary A. Wayman, Pullman, WA CPC .................................. C07K5/06078 (2013.01) (US) USPC ........................................................... S14/95 (73) Assignee: Washington State University, Pullman, WA (US) (57) ABSTRACT (21) Appl. No.: 14/038,973 (22) Filed: Sep. 27, 2013 Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been gen Related U.S. Application Data erated. These molecules have been shown or predicted to have (63) Continuation-in-part of application No. PCT/US2012/ therapeutic potential for numerous pathologies including 031815, filed on Apr. 2, 2012. dementia (e.g. Alzheimer's) and Parkinson's disease. Patent Application Publication Feb. 20, 2014 Sheet 1 of 40 US 2014/0051633 A1 a --- --- - - -s ------- CS -8- Scopolarine s -k- Oii exa-ow " -: N. Sks s i. Y s re. Dihexa-high as: ^ N.-- st-scs:- -------------------------------------------------------------------------------------------. Acquisition (days) Figure 1A -8-CSF -- -8- Scopoanine i. --- - -k- Dihexa-ow -- hexa-high reta-or 2 3 4 5 6 7 8 Acquisition (days) Figure 1B -8- vici-treated -- hexa Acquisition (days) Figure 1C Patent Application Publication Feb.
    [Show full text]
  • Pure Pricing List
    Product Name/Description Typical Directions 0.3cc Insulin Syringe UAD 0.5cc Insulin Syringe UAD 1cc Insulin Syringe UAD 1mL Syringe with 27g x 1/2" needle UAD Amlexanox 40mg Capsules 1 po QD Ammonium Tetrathiomolybdate 50mg Capsule 1 po BID AOD 9604 600mcg Capsule 1 po QD 0.25mL (300mcg) SQ QD 30 minutes before AOD 9604 1200mcg/mL Injection breakfast OR QHS on empty stomach AOD 9604 600mcg/mL Transdermal Cream Apply topically QD AOD 9604 600mcg/mL Transdermal Cream Apply topically QD AOD/BPC 2mg/2mg Cream Apply topically QD to wound AOD/BPC 2mg/2mg Cream Apply topically QD to wound ARA 290 4mg/mL Injection 0.5mL-1mL (2-4mg) SQ QD Ascorbic Acid 500mg/mL As directed BPC-157 500mcg Capsules 1 po QD BPC-157 500mcg Mini-Troche 1 SL QD BPC-157 2mg/mL Cream Apply topically QD BPC-157 2000mcg/mL Injection 0.25mL (500mcg) SQ QD BPC-157 200mcg/mL Eye Drops 1 drop into affected eye(s) BID 1 spray (200mcg) into one nostril QD **Alternate BPC-157 200mcg/0.1mL Nasal Spray nostrils QD** 1 spray (500mcg) into one nostril QD-BID BPC-157 500mcg/0.1mL Nasal Spray **Alternate nostrils QD** BPC-157/ Synapsin 5mg/50mg/mL 1 spray into one nostril 2-3 times daily BPC-157 1mg/mL Oral Paste Use to brush teeth 1-2 times daily BPC-157/GHK-Cu 2mg/2mg/mL Topical Cream Apply topically QD to wound 0.05mL (100mcg) SQ QHS 5 nights on, 2 nights CJC/Ipamorelin 2000mcg/2000mcg Injection off (Increase GH, sleep)… 0.05mL 3-4 times daily 5 days on, 2 days off (weight loss) 0.05mL (100mcg) SQ QHS 5 nights on, 2 nights CJC/Ipamorelin 2000mcg/2000mcg Injection off (Increase GH,
    [Show full text]
  • Counteracting EMF Toxicity with Peptides (Forget Global Warming Emfs Are Killing Us)
    Counteracting EMF Toxicity with Peptides (Forget Global Warming EMFs are Killing Us) Dr. Kent Holtorf, MD Medical Director/CEO, Holtorf Medical Group (HoltorfMed.com) Medical Director/CEO, National Academy of Hypothyroidism (NAHypothyroidism.org) Medical Director, Integrative Peptides (IntegrativePeptides.com) Disclosure Statement Owner/CEO - Holtorf Medical Group HoltorfMed.com A multi-specialty medical group specializing in the treatment of complex endocrine dysfunction, CFS/fibromyalgia, chronic infectious diseases, immune dysfunction, neurodegenerative disease, and other complex chronic illnesses. Chief Medical Officer - The Non-Profit, The National Academy of Hypothyroidism and Integrative Sciences (NAHIS) NAHypothyroidism.org NAHIS is a non- profit, multidisciplinary medical society dedicated to the dissemination of new information on the diagnosis and treatment of hypothyroidism and complex conditions. NAHIS receives grants for clinical and laboratory research for novel methods in the diagnosis and treatment of hypothyroidism and chronic illnesses Chief Medical Officer - Integrative Peptides IntegrativePeptides.com Currently sells orally active and absorbable natural peptides in oral supplement form with unique delivery methods 2 Disclosure Statement Important Disclaimer In the interest of full disclosure, I am the All studies have limitations, and there is no perfect study. As with other studies, the studies Chief Medical Officer of Integrative Peptides. mentioned in this presentation and during the summit have limitations that should be considered when evaluating the efficacy of any treatment, including peptides, and determining the The opinions expressed are mine and do not appropriateness of peptide therapy for consumer use. A short summary, the abstract or reference to necessarily reflect those of Integrative a study may be discussed or provided. We are happy to provide you the entire study for your review of any study discussed, mentioned, presented or referenced.
    [Show full text]
  • PEPTIDE INFORMATION Contact Kitt Burkley for Pricing 855-762-4878
    PEPTIDE INFORMATION Contact Kitt Burkley for pricing 855-762-4878 AOD 9604 AOD 9604 works by mimicking the way natural HGH regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified HGH. Studies have suggested that AOD 9604 has an ability to stimulate lipolysis and inhibit lipogenesis. In addition AOD 9604 possesses other regenerative properties associated with growth hormone. Trials have been undertaken to determine the possible application of AOD 9604 in osteoarthritis and hypercholesterolemia, as well as for bone and cartilage repair. Results of oral glucose tolerance testing have demonstrated that AOD 9604 has no negative effect on carbohydrate metabolism, and it does not affect serum IGF-1 levels. AOD 9604 has an excellent safety profile and is generally well tolerated. It has attained Human GRAS status in the US. AOD 9604 600mcg/ml Cream – 30g AOD 9604* 0.5mg Troche BPC-157 (Body Protection Compound) BPC-157 promotes muscle and tendon healing, increases angiogenesis and decreases inflammatory response. Produces more type 1 collagen and has excellent potential for diabetic wound healing. BPC- 157 is highly stable, resistant to both hydrolysis and enzyme digestion. It can be given orally as well as administered subcutaneously or intramuscularly – no carrier molecule is required. This peptide has significant anti-inflammatory modulating effects. BPC-157 promotes tissue healing through signaling pathways – it provides specific response to particular injury thru cell signaling. BPC- 157 can be used continuously as body protective, or for specific period to treat body injury. BCP-157 is in clinical trials for IBD.
    [Show full text]
  • Formularies Pricing Sheet
    Regenerative Practices of America (T-5) Pricing is effective from 04/06/2021 to 12/31/2021 Multiple Locations *Once Signed and Returned* MEDICATION STRENGTH Form PRICE BHRT Pellets & Numbing Cream 6mg $ 11.00 10mg $ 11.00 12.5mg $ 11.00 Estradiol (3mm) 15mg Pellet $ 11.00 18mg $ 11.00 20mg $ 11.00 25mg $ 11.00 50mg $ 18.00 Progesterone (3mm) Pellet 100mg $ 18.00 12.5mg $ 11.00 25mg $ 11.00 37.5mg $ 11.00 50mg $ 13.00 Testosterone (12.5mg - 100mg are 3mm, 200mg is 4.5mm) Pellet 62.5mg $ 13.00 87.5mg $ 14.00 100mg $ 16.00 200mg $ 21.00 100mg/4mg $ 19.00 Testosterone/Anastrozole 200mg/8mg Pellet $ 28.00 (100mg/4mg is 3mm, all others are 4.5mm) 200mg/20mg $ 33.00 Disposable-Plastic Tip (3.2mm) Each $ 18.00 Disposable-Stainless Steel Tip Each $ 21.00 (3.2mm & 4.5mm)) Trocar Kit for Pellet Insertion Reusable-Titanium Or Call For Stainless Steel (3.2mm & Each Pricing 4.5mm) 3.2mm Trocars are to be used with the 3mm Pellets & 4.5mm Trocars are to be used with 4.5mm Pellets Benzocaine/Lidocaine/Teracaine (BLT), Topi-Pump, 120gm 20%/6%/4% Cream $ 67.00 Peptides AOD 9604, 30gm 0.6mg/mL Cream $ 118.00 AOD 9604, 5mL Vial *Ship Cold* 1.2mg/mL Injectable $ 118.00 BPC-157, 5mL Vial *Ship Cold* 2mg/mL Injectable $ 126.00 Regenerative Practices of America (T-5) Pricing is effective from 04/06/2021 to 12/31/2021 Multiple Locations *Once Signed and Returned* 250mcg (0.25 mg) Capsule $ 74.00 BPC-157, Qty #30 *Ship Cold* 500mcg (0.5mg) Capsule $ 105.00 1mg Capsule $ 120.00 1mg/1mg/mL Injectable $ 55.00 CJC-1295/Ipamorelin, 2mL Vial *Ship Cold* 2mg/1mg/mL Injectable
    [Show full text]
  • Product Data Sheet
    Inhibitors Product Data Sheet Dihexa • Agonists Cat. No.: HY-16969 CAS No.: 1401708-83-5 Molecular Formula: C₂₇H₄₄N₄O₅ • Molecular Weight: 504.66 Screening Libraries Target: c-Met/HGFR Pathway: Protein Tyrosine Kinase/RTK Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (198.15 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.9815 mL 9.9077 mL 19.8153 mL Stock Solutions 5 mM 0.3963 mL 1.9815 mL 3.9631 mL 10 mM 0.1982 mL 0.9908 mL 1.9815 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution BIOLOGICAL ACTIVITY Description Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease[1][2]. IC₅₀ & Target Kd: 65 pM (HGF)[1] In Vitro Dihexa binds with high affinity to HGF and both dihexa and its parent compound Norleucine 1-AngIV induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.
    [Show full text]
  • Product Catalogwells Pharmacy Network
    2020 PRODUCT CATALOGWELLS PHARMACY NETWORK 800-622-4510 [email protected] wellsrx.com A COMPOUNDING PHARMACY DEDICATED CONTENT TO QUALITY, SERVICE AND QUESTIONS 1 SAFETY. 503B LICENSING 2 Wells Pharmacy Network is a privately held nationwide compounding pharmacy specializing in wellness, anti- aging, weight management, sexual wellness, aesthetic PRODUCTS dermatology and thyroid and adrenal health. LIST OF PRODUCTS 3 Our mission is to elevate compounding industry standards through a unique combination of superior science and service. This includes operating a 21,000 503A pharmacy that meet the patients specifi c compounding needs and as well as a 4,000 SF FDA Registered 503B Outsourcing Facility PELLETS that dispenses bulk medication for physician o ce use. ABOUT PELLETS 4 Wells Pharmacy Network uses the most advanced instrumentation, including in-house sterility and endotoxin STERILE 6 testing, which allow us to control the quality and timely IMPLANTABLE delivery of our preparations, such as sterile implantable HORMONE PELLETS bioidentical hormone pellets and other custom medications. Patient safety is our priority and our commitment to the quality of the preparations we compound is the most important thing we do each and every day. Learn more at: WELLSRX.COM CONTENT PEPTIDES AOD 9604 7 BPC-157 8 SEXUAL PRODUCTS CJC-1295/IPAMORELIN 9 WELLNESS DIHEXA 10 DSIP 11 PT-141 NASAL SPRAY 23 (EROS LOVE SPRAY) GHK-CU 12 SEXUAL WELLNESS 24 IBUTAMOREN 13 PROGRAM FOR IPAMORELIN 14 WOMEN KISSPEPTIN-10 15 SEXUAL WELLNESS 25 PROGRAM FOR MELATONAN II 16
    [Show full text]
  • Pharmacokinetic Characterization of Angiotensin Iv Analogs With
    PHARMACOKINETIC CHARACTERIZATION OF ANGIOTENSIN IV ANALOGS WITH THERAPEUTIC POTENTIAL FOR CANCER AND DEMENTIA. By ALENE MCCOY A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY WASHINGTON STATE UNIVERSITY Graduate Program in Pharmacology and Toxicology MAY 2010 To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation of ALENE MCCOY find it satisfactory and recommend that it be accepted. Joseph W. Harding, Ph.D., Chair John W. Wright, Ph.D. Neal Davies, Ph.D. Raymond Quock, Ph.D. Heiko Jansen, Ph.D. ii ACKNOWLEDGEMENTS There are many people without whose support the research presented in this dissertation would not have been possible. First and foremost, I would like to thank my thesis advisor Joseph Harding for his professional and personal guidance and support throughout my graduate career. Your great generosity and wisdom will forever be an inspiration to me. I would also like to thank my thesis committee and the faculty in the Program in Pharmacology and Toxicology. Thank you for always being available and for your professional guidance. Special thanks to Neal Davies for your generous assistance with all of my pharmacokinetic queries. Thanks to all of the past employees of Pacific Northwest Biotechnology and to present members of the Harding laboratory. You made PNB and the Harding lab a wonderful place to work and taught me a great deal. I would especially like to acknowledge Brent Yamamoto who was a mentor to me during my first three years in graduate school, and my good friend Caroline Benoist.
    [Show full text]
  • Modified Polysaccharides, Method for Their Production and Their Use
    (19) TZZ _¥_T (11) EP 2 899 213 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.07.2015 Bulletin 2015/31 C08B 1/00 (2006.01) C08B 1/06 (2006.01) C08B 11/00 (2006.01) C08B 15/06 (2006.01) (2006.01) (2006.01) (21) Application number: 14152669.9 C08B 31/00 C08B 31/08 C08B 37/00 (2006.01) C09D 101/08 (2006.01) (2006.01) (2006.01) (22) Date of filing: 27.01.2014 C09D 101/26 C09D 103/04 C09D 103/08 (2006.01) C09D 105/00 (2006.01) C09J 101/08 (2006.01) C09J 101/26 (2006.01) C09J 103/04 (2006.01) C09J 103/08 (2006.01) C09J 105/00 (2006.01) (84) Designated Contracting States: • Zajaczkowski-Fischer, Marta AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 67141 Neuhofen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Kindler, Alois PL PT RO RS SE SI SK SM TR 67269 Grünstadt (DE) Designated Extension States: BA ME (74) Representative: Reitstötter Kinzebach Patentanwälte (71) Applicant: BASF SE Im Zollhof 1 67056 Ludwigshafen (DE) 67061 Ludwigshafen (DE) (72) Inventors: • Granström, Mari 00120 Helsinki (FI) (54) Modified polysaccharides, method for their production and their use (57) The present invention relates to a method for ride, ethylenically unsaturated polysaccharides obtaina- producing an ether modified polysaccharide, ether mod- ble by said method, polymers comprising those unsatu- ified polysaccharide obtainable by said method and the rated polysaccharides in polymerized form and the use use thereof.
    [Show full text]
  • Tailor Made Compounding
    PEPTIDE CATALOG TAILOR MADE COMPOUNDING Phone: 1 859 887 0013 | Email: [email protected] Our Story | 04-05 MK-677 | 36 Peptide Fact Sheets | 06-55 Myristyl | 37 3-Desoxy DHEA | 08 NMN | 38 5-Amino-1MQ | 09 PEG-MGF | 39 Amlexanox | 10 Pentosan Polysulfate | 40 AMT | 11 PNC-27 | 41 Aniracetam | 12 PT-141 | 42 AOD 9604 | 13 PTD-DBM | 43 AOD 9604 + HA | 14 RG3, Methylcobalamin, NAD+ | 44 BPC-157 | 15 Sarms LGD-4033 | 45 Cerebrolysin | 16 Selank | 46 CJC-1295 | 17 Semax | 47 DHH-B | 18 Tesamorelin | 48 Dihexa | 19 Tesofensine | 49 DSIP | 20 Tetradecylthioacetic Acid (TTA) | 50 Eclomiphene | 21 Thymosin Alpha-1 | 51 Epitalon | 22 Thymosin Beta | 52 FGL (l) | 23 VIP | 53 GHK-Cu | 24 Zinc Thymulin | 54 TABLE OF TABLE Glycyrrhetinic Acid & Aminophylline Dosing Charts | 25 56-62 Transdermal Fat Loss Cream Licensed States | 64-65 IGF-1 | 26 TMC App | 66-67 Ipamorelin | 27 Contact Us | 68 iRGD | 28 Kisspeptin-10 | 29 KPV | 30 Leuphasyl | 31 LL-37 | 32 Malanotan II | 33 Met-Enkephalin | 34 MOTS-c | 35 CONTENTS Tailor Made Compounding was launched United States. Since the inception of TMC, in the U.S. in January of 2016. We have we have sourced and compounded over 40 since become a major contributor to unique peptides. We are proud to be the peptide medicines in the integrative first in the United States to offer health space. compounds like CJC 1295, Bremelanotide, OUR PT 141, BPC-157, and Epitalon and Through our compounding expertise, continue to introduce new and exciting knowledge and experience, we have compounds to our formulary.
    [Show full text]
  • AX Pharmaceutical Corp “We Supply High Quality Products All for Health”
    AX Pharmaceutical Corp “We supply high quality products all for Health” Product List 1-Dodecanol 2,4-Dinitrochlorobenzene 2-Deoxy-D-Glucose 2-Methoxyestradiol 4-Aminopyridine 4-Methoxyphenol 5-Alpha-Hydroxy-Laxogenin 5-Amino-1-methylquinolinium 5-Aminolevulinic Acid Iodide 5-Aminosalicylic Acid 5-Fluororacil 5-Hydroxytryptophan Acebutolol HCl Acepromazine Maleate Acetazolamine Acetohydroxamic Acid Acetyl Dipeptide Acetyl Hexapeptide-3 Acetyl Tributyl Citrate ACTH 1-24 ACTH 1-39 Acyclovir Adapalene Adenosine 5 Monophosphate Adenosine 5 Tri-Phosphate Adenosylcobalamin Afoxolaner Disodium salt Alanyl-L-Glutamine Albendazole Alendronate Sodium Alendronic Acid Alpelisib Alpha Ketoglutaric Acid Alpha Lipoic Acid Alpha-Melanocyte-Stimulating Alprostadil Hormone Altrenogest Amantadine HCl Ambrisentan Ambroxol HCl Aminobenzoic Acid (PABA) Aminopentamide Sulfate Aminophylline Anhydrous Amitraz Amitriptyline HCl Amlexanox Amlodipine Besylate Amoxicillin Trihydrate Amphotericin B Anastrozole Aniracetam AOD 9604 Trifluoroacetate Aprepitant Aripiprazole Artemisinin Ascorbic Acid Ascorbyl Glucoside Atenolol Atipamezole HCl Atorvastatin Atovaquone Atropine Sulfate Monohydrate Auranofin Axitinib Azaperone Tartrate Azelaic Acid Azelastine HCl Azithromycin Dihydrate Azlocillin Sodium Bacitracin Zinc Baclofen Benazepril HCl Benzocaine Betadex (Beta Cyclodextrin) Betadex Sulfobutyl Ether Sodium Betahistine Bethanechol Chloride Bezafibrate Bifonazole Bimatoprost Bismuth Subsalicylate Bitter Orange Extract BPC 157 Bremelanotide Acetate (PT-141) Brimonidine
    [Show full text]
  • Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes
    cells Review Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes Sevda Gheibi *, Tania Singh, Joao Paulo M. C. M. da Cunha , Malin Fex and Hindrik Mulder * Unit of Molecular Metabolism, Lund University Diabetes Centre, Jan Waldenströms gata 35, Box 50332, SE-202 13 Malmö, Sweden; [email protected] (T.S.); [email protected] (J.P.M.C.M.d.C.); [email protected] (M.F.) * Correspondence: [email protected] (S.G.); [email protected] (H.M.) Received: 18 September 2020; Accepted: 9 November 2020; Published: 12 November 2020 Abstract: Type 2 diabetes, characterized by dysfunction of pancreatic β-cells and insulin resistance in peripheral organs, accounts for more than 90% of all diabetes. Despite current developments of new drugs and strategies to prevent/treat diabetes, there is no ideal therapy targeting all aspects of the disease. Restoration, however, of insulin-producing β-cells, as well as insulin-responsive cells, would be a logical strategy for the treatment of diabetes. In recent years, generation of transplantable cells derived from stem cells in vitro has emerged as an important research area. Pluripotent stem cells, either embryonic or induced, are alternative and feasible sources of insulin-secreting and glucose-responsive cells. This notwithstanding, consistent generation of robust glucose/insulin-responsive cells remains challenging. In this review, we describe basic concepts of the generation of induced pluripotent stem cells and subsequent differentiation of these into pancreatic β-like cells, myotubes, as well as adipocyte- and hepatocyte-like cells.
    [Show full text]